| 19.37 0.08 (0.41%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.12 | 1-year : | 27.01 |
| Resists | First : | 19.79 | Second : | 23.12 |
| Pivot price | 17.72 |
|||
| Supports | First : | 16.38 | Second : | 14.27 |
| MAs | MA(5) : | 18.84 |
MA(20) : | 17.59 |
| MA(100) : | 15.76 |
MA(250) : | 0 | |
| MACD | MACD : | 0.7 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 90.7  |
D(3) : | 88.6 |
| RSI | RSI(14): 66.4 |
|||
| 52-week | High : | 19.79 | Low : | 7.84 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BWAY ] has closed below upper band by 11.2%. Bollinger Bands are 66.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 19.72 - 19.8 | 19.8 - 19.87 |
| Low: | 18.1 - 18.2 | 18.2 - 18.28 |
| Close: | 19.2 - 19.36 | 19.36 - 19.5 |
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Wed, 24 Dec 2025
Optimistic Investors Push BrainsWay Ltd. (TLV:BWAY) Shares Up 27% But Growth Is Lacking - simplywall.st
Tue, 23 Dec 2025
BrainsWay Ltd.'s (TLV:BWAY) 27% Share Price Surge Not Quite Adding Up - simplywall.st
Tue, 23 Dec 2025
BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens - Yahoo Finance
Mon, 22 Dec 2025
Major insurer adds non-drug depression treatment option for teens 15 and up - Stock Titan
Thu, 13 Nov 2025
BrainsWay (NASDAQ: BWAY) wins FDA 510(k) to add Deep TMS adjunct for MDD in ages 15–21 - Stock Titan
Thu, 13 Nov 2025
Brainsway Reports Strong Q3 2025 Growth and Strategic Advances - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 20 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 6.1 (%) |
| Held by Institutions | 31.1 (%) |
| Shares Short | 53 (K) |
| Shares Short P.Month | 73 (K) |
| EPS | 0.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.78 |
| Profit Margin | 12.7 % |
| Operating Margin | 9.2 % |
| Return on Assets (ttm) | 1.9 % |
| Return on Equity (ttm) | 10.9 % |
| Qtrly Rev. Growth | 28.7 % |
| Gross Profit (p.s.) | 1.87 |
| Sales Per Share | 2.5 |
| EBITDA (p.s.) | 0.21 |
| Qtrly Earnings Growth | 100 % |
| Operating Cash Flow | 22 (M) |
| Levered Free Cash Flow | 9 (M) |
| PE Ratio | 60.53 |
| PEG Ratio | 0 |
| Price to Book value | 10.82 |
| Price to Sales | 7.72 |
| Price to Cash Flow | 17.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|